| 119.99 0 (0%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Heska Corporation provides specialized diagnostic and animal health products, predominantly for canine and feline veterinary care markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Its product line includes a variety of veterinary chemistry analyzers: the Element DC, DCX, and DC5x series, along with the Element RC, RCX, and RC3X systems, all tailored for blood chemistry and electrolyte analysis. For hematological assessments, Heska offers the Element HT5 and scil Vet abc Plus analyzers, capable of measuring blood cell and platelet counts, as well as hemoglobin levels. The company also supplies Element POC analyzers for blood gas and electrolyte testing, Element i immunodiagnostic analyzers, and the Element COAG and Element AIM veterinary analyzers for coagulation studies. Beyond analytical instruments, Heska's offerings extend to advanced imaging and clinical solutions such as HeskaView Telecytology, which provides automated microscopic slide scanning equipment for clinics, and IV infusion pumps. They also distribute digital radiography hardware, including mobile units, sophisticated ultrasound systems, and Cloudbank, a web-based platform for image storage. For rapid, in-clinic detection, point-of-care products are available to identify antigens and antibodies associated with infectious and parasitic diseases in animals. Therapeutic options include Tri-Heart Plus chewable tablets for treating canine heartworm, ascarid, and hookworm infections. The company also specializes in allergy management, offering ALLERCEPT definitive allergen panels for diagnosis and personalized therapy shots or drops. Furthermore, Heska develops a range of vaccines for bovine health. It supplies biological and pharmaceutical products to other animal health companies and offers comprehensive turnkey services encompassing research, licensing, production, labeling, packaging, validation support, and distribution. Products are distributed to veterinarians via a direct telephone sales force, third-party distributors, trade shows, print advertisements, and other strategic partnerships. Founded in 1988, the company was initially known as Paravax, Inc. before rebranding as Heska Corporation in 1995. Its corporate headquarters are located in Loveland, Colorado.
Sun, 21 May 2023
hska-20221231 - SEC.gov
Tue, 04 Apr 2023
Heska tells employees it hopes to retain workforce after $1.3B Mars acquisition - Loveland Reporter-Herald
Mon, 03 Apr 2023
Mars to acquire Heska, global provider of advanced veterinary diagnostic and specialty solutions - Mars, Incorporated
Tue, 03 Jan 2023
Heska Corporation Completes Acquisition of LightDeck Diagnostics - PR Newswire
Mon, 12 Sep 2022
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts - PR Newswire
Fri, 03 Jun 2022
Heska Corporation (HSKA) Share Price Today | Heska (HSKA) Live NSE/BSE - Value Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|